[go: up one dir, main page]

WO2018029474A3 - Anti-icos antibodies - Google Patents

Anti-icos antibodies Download PDF

Info

Publication number
WO2018029474A3
WO2018029474A3 PCT/GB2017/052352 GB2017052352W WO2018029474A3 WO 2018029474 A3 WO2018029474 A3 WO 2018029474A3 GB 2017052352 W GB2017052352 W GB 2017052352W WO 2018029474 A3 WO2018029474 A3 WO 2018029474A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
icos
cells
icos antibodies
stimulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2017/052352
Other languages
French (fr)
Other versions
WO2018029474A2 (en
Inventor
Richard Charles Alfred SAINSON
Stephen John ARKINSTALL
Jamie Iain Campbell
Mohammed Hanif ALI
E-Chiang Lee
Matthew John Mccourt
Nikole SANDY
Cassandra VAN KRINKS
Volker Germaschewski
Ian Kirby
Miha Kosmac
Thomas Gallagher
Cecilia DEANTONIO
Stephen Douglas GILLIES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1615224.1A external-priority patent/GB201615224D0/en
Priority claimed from GBGB1615335.5A external-priority patent/GB201615335D0/en
Priority claimed from US15/354,971 external-priority patent/US9617338B1/en
Priority claimed from GBGB1620414.1A external-priority patent/GB201620414D0/en
Priority claimed from GBGB1621782.0A external-priority patent/GB201621782D0/en
Priority claimed from GBGB1702338.3A external-priority patent/GB201702338D0/en
Priority claimed from GBGB1702339.1A external-priority patent/GB201702339D0/en
Priority claimed from GBGB1703071.9A external-priority patent/GB201703071D0/en
Priority claimed from PCT/GB2017/051796 external-priority patent/WO2017220990A1/en
Priority claimed from GBGB1709818.7A external-priority patent/GB201709818D0/en
Priority to RU2019104980A priority Critical patent/RU2764548C2/en
Priority to KR1020197006706A priority patent/KR102604433B1/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to CA3032897A priority patent/CA3032897A1/en
Priority to KR1020237009918A priority patent/KR20230044038A/en
Priority to BR112019002529A priority patent/BR112019002529A2/en
Priority to CN202310348318.8A priority patent/CN117736325A/en
Priority to JP2019529699A priority patent/JP7198752B2/en
Priority to CN202310636091.7A priority patent/CN116640214A/en
Priority to US16/323,980 priority patent/US11858996B2/en
Priority to CN201780045638.9A priority patent/CN109689688B/en
Priority to EP17752162.2A priority patent/EP3497128A2/en
Priority to US15/698,600 priority patent/US9957323B2/en
Priority to PCT/GB2017/053826 priority patent/WO2018115859A1/en
Priority to JP2019533195A priority patent/JP7290568B2/en
Priority to US16/471,161 priority patent/US20200190191A1/en
Priority to EP17840565.0A priority patent/EP3559041A1/en
Publication of WO2018029474A2 publication Critical patent/WO2018029474A2/en
Publication of WO2018029474A3 publication Critical patent/WO2018029474A3/en
Anticipated expiration legal-status Critical
Priority to US17/727,288 priority patent/US20220380467A1/en
Priority to US17/727,309 priority patent/US20220403029A1/en
Priority to JP2022089801A priority patent/JP7448586B2/en
Priority to JP2023016174A priority patent/JP7750887B2/en
Priority to US18/499,431 priority patent/US20240158502A1/en
Priority to JP2023205810A priority patent/JP2024028862A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti- ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
PCT/GB2017/052352 2016-06-20 2017-08-09 Anti-icos antibodies Ceased WO2018029474A2 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
JP2019529699A JP7198752B2 (en) 2016-08-09 2017-08-09 Anti-ICOS antibody
CN202310636091.7A CN116640214A (en) 2016-08-09 2017-08-09 Isolated antibodies and uses thereof
US16/323,980 US11858996B2 (en) 2016-08-09 2017-08-09 Anti-ICOS antibodies
CN201780045638.9A CN109689688B (en) 2016-08-09 2017-08-09 anti-ICOS antibody
EP17752162.2A EP3497128A2 (en) 2016-08-09 2017-08-09 Anti-icos antibodies
CN202310348318.8A CN117736325A (en) 2016-08-09 2017-08-09 Isolated antibodies and uses thereof
KR1020237009918A KR20230044038A (en) 2016-08-09 2017-08-09 Anti-icos antibodies
BR112019002529A BR112019002529A2 (en) 2016-08-09 2017-08-09 isolated antibody, composition, method for modulating t-cell balance, method for treating a therapy-treatable disease or condition, method for treating cancer, igg1 antibody combination, anti-ics antibody, transgenic non-human mammal, and method for producing a antibody
RU2019104980A RU2764548C2 (en) 2016-08-09 2017-08-09 Anti-icos antibodies
CA3032897A CA3032897A1 (en) 2016-08-09 2017-08-09 Anti-icos antibodies
KR1020197006706A KR102604433B1 (en) 2016-08-09 2017-08-09 anti-ICOS antibodies
US15/698,600 US9957323B2 (en) 2016-06-20 2017-09-07 Anti-ICOS antibodies
EP17840565.0A EP3559041A1 (en) 2016-12-20 2017-12-19 Multispecific antibody with combination therapy for immuno-oncology
US16/471,161 US20200190191A1 (en) 2016-12-20 2017-12-19 Multispecific antibody with combination therapy for immuno-oncology
JP2019533195A JP7290568B2 (en) 2016-12-20 2017-12-19 Multispecific antibodies in combination therapy for cancer immunotherapy
PCT/GB2017/053826 WO2018115859A1 (en) 2016-12-20 2017-12-19 Multispecific antibody with combination therapy for immuno-oncology
US17/727,309 US20220403029A1 (en) 2016-08-09 2022-04-22 Anti-icos antibodies
US17/727,288 US20220380467A1 (en) 2016-08-09 2022-04-22 Anti-icos antibodies
JP2022089801A JP7448586B2 (en) 2016-08-09 2022-06-01 Anti-ICOS antibody
JP2023016174A JP7750887B2 (en) 2016-12-20 2023-02-06 Multispecific antibodies in combination therapy for cancer immunotherapy
US18/499,431 US20240158502A1 (en) 2016-08-09 2023-11-01 Anti-icos antibodies
JP2023205810A JP2024028862A (en) 2016-08-09 2023-12-06 Anti-ICOS antibody

Applications Claiming Priority (34)

Application Number Priority Date Filing Date Title
GB201613683 2016-08-09
GB1613683.0 2016-08-09
GB1615224.1 2016-09-07
GBGB1615224.1A GB201615224D0 (en) 2016-09-07 2016-09-07 Antibodies
GBGB1615335.5A GB201615335D0 (en) 2016-09-09 2016-09-09 Antibodies and immunocytokines
GB1615335.5 2016-09-09
US15/354,971 2016-11-17
US15/354,971 US9617338B1 (en) 2016-06-20 2016-11-17 Antibodies and immunocytokines
GBGB1620414.1A GB201620414D0 (en) 2016-12-01 2016-12-01 Antibodies
GB1620414.1 2016-12-01
GB1621782.0 2016-12-20
GBGB1621782.0A GB201621782D0 (en) 2016-12-20 2016-12-20 Antibodies and immunocytokines PD-L1 specific antibodies and PD-L1 specific immunocytokines
GB1702339.1 2017-02-13
GBGB1702339.1A GB201702339D0 (en) 2017-02-13 2017-02-13 Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines
GBGB1702338.3A GB201702338D0 (en) 2017-02-13 2017-02-13 Antibodies and immunocytokines PD-L1 specific antibodies and specific immunocytokines
GB1702338.3 2017-02-13
GB1703071.9 2017-02-24
GBGB1703071.9A GB201703071D0 (en) 2017-02-24 2017-02-24 Antibodies
US15/480,525 2017-04-06
US15/480,525 US10604576B2 (en) 2016-06-20 2017-04-06 Antibodies and immunocytokines
GBPCT/GB2017/051796 2017-06-20
GBGB1709818.7A GB201709818D0 (en) 2017-06-20 2017-06-20 Antibodies
GB1709818.7 2017-06-20
PCT/GB2017/051796 WO2017220990A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 antibodies
PCT/GB2017/051794 WO2017220988A1 (en) 2016-06-20 2017-06-20 Multispecific antibodies for immuno-oncology
TW106120562A TWI784957B (en) 2016-06-20 2017-06-20 Immunocytokines
TW106120563 2017-06-20
GBPCT/GB2017/051795 2017-06-20
GBPCT/GB2017/051794 2017-06-20
TW106120564 2017-06-20
TW106120562 2017-06-20
TW106120563A TW201803905A (en) 2016-06-20 2017-06-20 Multiple specific antibody for immunooncology
PCT/GB2017/051795 WO2017220989A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 and il-2 cytokines
TW106120564A TWI640536B (en) 2016-06-20 2017-06-20 antibody

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/480,525 Continuation US10604576B2 (en) 2016-06-20 2017-04-06 Antibodies and immunocytokines

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US16/323,980 A-371-Of-International US11858996B2 (en) 2016-08-09 2017-08-09 Anti-ICOS antibodies
US15/698,600 Continuation US9957323B2 (en) 2016-06-20 2017-09-07 Anti-ICOS antibodies
US17/727,288 Continuation US20220380467A1 (en) 2016-08-09 2022-04-22 Anti-icos antibodies
US17/727,309 Division US20220403029A1 (en) 2016-08-09 2022-04-22 Anti-icos antibodies
US18/499,431 Division US20240158502A1 (en) 2016-08-09 2023-11-01 Anti-icos antibodies

Publications (2)

Publication Number Publication Date
WO2018029474A2 WO2018029474A2 (en) 2018-02-15
WO2018029474A3 true WO2018029474A3 (en) 2018-03-22

Family

ID=59713388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2017/052352 Ceased WO2018029474A2 (en) 2016-06-20 2017-08-09 Anti-icos antibodies

Country Status (1)

Country Link
WO (1) WO2018029474A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102604433B1 (en) 2016-08-09 2023-11-24 키맵 리미티드 anti-ICOS antibodies
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3793598A1 (en) * 2018-05-14 2021-03-24 Jounce Therapeutics, Inc. Methods of treating cancer
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CA3117746A1 (en) 2018-10-22 2020-04-30 Glaxosmithkline Intellectual Property Development Limited Dosing
GB201905552D0 (en) 2019-04-18 2019-06-05 Kymab Ltd Antagonists
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046293A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
WO2021057930A1 (en) * 2019-09-26 2021-04-01 Wuxi Biologics (Shanghai) Co., Ltd. A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof
EP4136113A1 (en) 2020-04-14 2023-02-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
WO2021209356A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
AU2021256925A1 (en) 2020-04-14 2022-11-03 Ares Trading S.A. Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
CN119855833A (en) * 2022-09-22 2025-04-18 安捷伦科技有限公司 Anti-human ICOS antibodies for use in Immunohistochemical (IHC) protocols and for diagnosis of cancer
CN118063611A (en) * 2024-01-25 2024-05-24 宁波大学附属第一医院 VHH chain of human ICOS targeted nanobody and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154177A2 (en) * 2015-03-23 2016-09-29 Jounce Therapeutics, Inc. Antibodies to icos

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
NL1003648C2 (en) 1996-07-19 1998-01-21 Carino Cornelis Sunderman Method and device for promoting the flue gas discharge of a fireplace.
JP3521382B2 (en) 1997-02-27 2004-04-19 日本たばこ産業株式会社 Cell surface molecules that mediate cell-cell adhesion and signal transduction
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (en) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let T cell co-stimulating polypeptide, monoclonal antibodies, and the production and use thereof
US7259247B1 (en) 1997-09-23 2007-08-21 Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes Anti-human T-cell costimulating polypeptide monoclonal antibodies
JP3871503B2 (en) 1999-08-30 2007-01-24 日本たばこ産業株式会社 Immune disease treatment
TWI263496B (en) 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
JP3597140B2 (en) 2000-05-18 2004-12-02 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
JP4212278B2 (en) 2001-03-01 2009-01-21 日本たばこ産業株式会社 Graft rejection inhibitor
JP2008501638A (en) 2004-04-23 2008-01-24 ドイツ連邦共和国 Method of treating T cell mediated pathology by in vivo depletion of ICOS positive cells
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CA2685465C (en) 2007-05-07 2020-02-25 Medimmune, Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
SMT202400136T1 (en) 2008-12-09 2024-05-14 Hoffmann La Roche Anti-pd-l1 antibodies and their use to enhance t-cell function
JO3672B1 (en) 2008-12-15 2020-08-27 Regeneron Pharma High Affinity Human Antibodies to PCSK9
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
DK2798950T4 (en) 2009-07-08 2023-05-15 Kymab Ltd Animal models and therapeutic molecules
EP3381937A3 (en) 2009-08-13 2018-10-31 The Johns Hopkins University Methods of modulating immune function
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
JP5894538B2 (en) 2010-02-04 2016-03-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ICOS critically regulates the proliferation and function of inflammatory human Th17 cells
SG186238A1 (en) 2010-06-17 2013-01-30 Kymab Ltd Animal models and therapeutic molecules
CA3050674C (en) 2011-03-31 2021-10-12 Julien FAGET Antibodies directed against icos and uses thereof
MX338353B (en) 2011-04-20 2016-04-13 Medimmune Llc ANTIBODIES AND OTHER MOLECULES THAT JOIN B7 - H1 AND PD - 1.
EP2720719A4 (en) 2011-06-15 2015-12-09 Glaxosmithkline Ip No 2 Ltd Method of selecting therapeutic indications
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
SMT202000561T1 (en) 2011-11-28 2021-01-05 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CN113967253A (en) 2012-05-15 2022-01-25 百时美施贵宝公司 Immunotherapy by disrupting PD-1/PD-L1 signaling
CN104736168B (en) 2012-05-31 2018-09-21 索伦托治疗有限公司 Antigen-binding protein that binds to PD-L1
WO2014033327A1 (en) 2012-09-03 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos for treating graft-versus-host disease
CA3139031A1 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
PT2925350T (en) 2012-12-03 2019-03-25 Bristol Myers Squibb Co Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
ME02917B (en) 2013-03-14 2018-10-20 Bristol Myers Squibb Co DR5 AGONISTS AND ANTI-PD COMBINATION - 1 ANTAGONISTS AND METHODS OF ADMINISTRATION
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
EP3060581A4 (en) 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
PT3094351T (en) 2014-01-15 2022-02-22 Kadmon Corp Llc Immunomodulatory agents
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
RU2690670C2 (en) 2014-03-12 2019-06-05 Ида Рисерч Энд Дивелопмент Ко., Лтд Reduced levels or activity of systemic regulatory t cells for treating disease or cns injury
CN106456756B (en) 2014-05-13 2021-04-23 免疫医疗有限公司 Anti-B7-H1 and Anti-CTLA-4 Antibodies for the Treatment of Non-Small Cell Lung Cancer
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
JP6666905B2 (en) 2014-05-29 2020-03-18 スプリング バイオサイエンス コーポレーション PD-L1 antibody and use thereof
CN110156892B (en) 2014-07-03 2023-05-16 百济神州有限公司 anti-PD-L1 antibodies and their use as therapeutic and diagnostic agents
BR112017000497B1 (en) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc ISOLATED ANTIBODY, PROKARYOTIC HOST CELL, IMMUNOCONJUGATE AND METHOD FOR DETECTING THE PRESENCE OR LEVEL OF PD-L1 EXPRESSION
NZ728749A (en) 2014-08-05 2023-06-30 Cb Therapeutics Inc Anti-pd-l1 antibodies
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
MA41414A (en) 2015-01-28 2017-12-05 Centre Nat Rech Scient ICOS AGONIST BINDING PROTEINS
BR112017019559B1 (en) 2015-03-13 2020-08-04 Cytomx Therapeutics, Inc ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE OF THESE
EP3277320A4 (en) 2015-03-30 2018-08-01 Stcube, Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN106397592A (en) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 Single-domain antibody directed at programmed death ligand (PD-L1) and derived protein thereof
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
AR105654A1 (en) 2015-08-24 2017-10-25 Lilly Co Eli ANTIBODIES PD-L1 (LINKING 1 OF PROGRAMMED CELL DEATH)
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154177A2 (en) * 2015-03-23 2016-09-29 Jounce Therapeutics, Inc. Antibodies to icos

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
@BULLET MICHAEL BRISKIN ET AL: "Efficacy of Anti-ICOS Agonist Monoclonal Antibodies in Preclinical Models Provides a Rationale for Clinical Development for cancer immunotherapy", 1 January 2015 (2015-01-01), XP055403162, Retrieved from the Internet <URL:https://www.sitcancer.org/HigherLogic/System/DownloadDocumentFile.ashx?DocumentFileKey=61eb1765-37fd-845a-f228-8d92af893886&forceDialog=1> [retrieved on 20170901] *
BOSCHETTI G ET AL: "W1803 Therapy With Anti-TNF+/- Antibody Enhances Number and Function of FOXP3+ Regulatory T Cells in Inflammatory Bowel Diseases", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, vol. 138, no. 5, 1 May 2010 (2010-05-01), pages S - 743, XP027025949, ISSN: 0016-5085, [retrieved on 20100427] *
CHRISTOPHER HARVEY ET AL: "Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 3, no. 2, 4 November 2015 (2015-11-04), pages 1, XP021235145, DOI: 10.1186/2051-1426-3-S2-O9 *
DENG ZHONG-BIN ET AL: "An agonist human ICOS monoclonal antibody that induces T cell activation and inhibits proliferation of a myeloma cell line", HYBRIDOMA AND HYBRIDOMICS, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 23, no. 3, 1 June 2004 (2004-06-01), pages 176 - 182, XP002657735, ISSN: 1536-8599 *
GEOK CHOO SIM ET AL: "IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients", JOURNAL OF CLINICAL INVESTIGATION, vol. 124, no. 1, 2 December 2013 (2013-12-02), US, pages 99 - 110, XP055441207, ISSN: 0021-9738, DOI: 10.1172/JCI46266 *
J. FAGET ET AL: "ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells", CANCER RESEARCH, vol. 72, no. 23, 1 December 2012 (2012-12-01), pages 6130 - 6141, XP055205105, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-2409 *
K.-S. LE ET AL: "Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy", CANCER RESEARCH, vol. 76, no. 16, 31 May 2016 (2016-05-31), US, pages 4648 - 4660, XP055405037, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-15-0589 *
KUTLU ELPEK ET AL: "A059: Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics", CANCER IMMUNOLOGY RESEARCH, vol. 4, no. 1 Supplement, 3 January 2016 (2016-01-03) - 20 April 2016 (2016-04-20), US, pages A059 - A059, XP055315154, ISSN: 2326-6066, DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A059 *
M. F. CHEVALIER ET AL: "Phenotype Alterations in Regulatory T-Cell Subsets in Primary HIV Infection and Identification of Tr1-like Cells as the Main Interleukin 10-Producing CD4+ T Cells", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 211, no. 5, 3 October 2014 (2014-10-03), CHICAGO, IL., pages 769 - 779, XP055441179, ISSN: 0022-1899, DOI: 10.1093/infdis/jiu549 *
P. SHARMA ET AL: "The future of immune checkpoint therapy", SCIENCE, vol. 348, no. 6230, 3 April 2015 (2015-04-03), pages 56 - 61, XP055402824, ISSN: 0036-8075, DOI: 10.1126/science.aaa8172 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *
SYLVIA FEYLER ET AL: "Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent", PLOS ONE, vol. 7, no. 5, 29 May 2012 (2012-05-29), pages e35981, XP055441216, DOI: 10.1371/journal.pone.0035981 *
TU JIAN-FEI ET AL: "Regulatory T cells, especially ICOS+ FOXP3(+) regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival", SCIENTIFIC REPORTS, vol. 6, October 2016 (2016-10-01), XP002777316 *
XIAOZHOU FAN ET AL: "Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 211, no. 4, 31 March 2014 (2014-03-31), US, pages 715 - 725, XP055414943, ISSN: 0022-1007, DOI: 10.1084/jem.20130590 *

Also Published As

Publication number Publication date
WO2018029474A2 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
WO2018029474A3 (en) Anti-icos antibodies
MX2020005463A (en) Cd47 antibodies and uses thereof for treating cancer.
JOP20200309A1 (en) Il-11 antibodies
SA523442262B1 (en) CD3 Binding Antibodies
ZA201905790B (en) Anti-lag-3 antibodies and uses thereof
MX2021011667A (en) Antibodies to icos.
PH12020552229A1 (en) Il-11ra antibodies
BR112019002529A2 (en) isolated antibody, composition, method for modulating t-cell balance, method for treating a therapy-treatable disease or condition, method for treating cancer, igg1 antibody combination, anti-ics antibody, transgenic non-human mammal, and method for producing a antibody
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
EA201992469A1 (en) ANTIGEN SPECIFIC IMMUNE EFFECTIVE CELLS
MY181106A (en) Anti-lag3 antibodies and uses thereof
MY200602A (en) Antibodies against tim3 and uses thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
MY187739A (en) Novel anti-pd-1 antibodies
MY202870A (en) Anti-ctla-4 antibodies and uses thereof
SA517381703B1 (en) Anti-C10orf54 Antibodies And Uses Thereof
PH12017501166A1 (en) Antibodies to tight
EA201891435A1 (en) HUMANIZED MONOCLONAL ANTIBODIES, MONOCLONAL ANTIBODIES MOUSE OR CHEMERIC MONOCLONAL ANTIBODIES AGAINST CD47
EP3964527A3 (en) Combination therapy for cancer
PH12016502370A1 (en) Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
WO2016070089A3 (en) Anti-cs1 antibodies and antibody drug conjugates
WO2015195555A8 (en) Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
EP4316596A3 (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
WO2014153056A8 (en) Cancer treatment using antibodies that bind cell surface grp78

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17752162

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3032897

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019529699

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197006706

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017752162

Country of ref document: EP

Effective date: 20190311

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019002529

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112019002529

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190207

WWG Wipo information: grant in national office

Ref document number: 201917008076

Country of ref document: IN